Get started
Author

Susanne Hegewisch-Becker

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
2016 · D.P. Modest, I. Ricard, et al. · Annals of Oncology · 374
PDF
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
2010 · F Lordick, B Luber, et al. · British Journal of Cancer · 176
PDF
Blood‐based detection of RAS mutations to guide anti‐ EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue‐based RAS testing
2017 · Wolff Schmiegel, Rodney J. Scott, et al. · Molecular Oncology · 153
PDF
Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients
2008 · J Panse, K Friedrichs, et al. · British Journal of Cancer · 135
PDF
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
2013 · S. Kubicka, R. Greil, et al. · Annals of Oncology · 108
PDF
Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group
2021 · Ralf‐Dieter Hofheinz, Susanne Hegewisch‐Becker, et al. · International Journal of Cancer · 103
PDF
Bone Marrow Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
1997 · M. Stockshläder, S. Hegewisch-Becker, et al. · Hämatologie und Bluttransfusion · 77
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
2013 · W. Schmiegel, A. Reinacher-Schick, et al. · Annals of Oncology · 70
Current options in treatment of anthracycline-resistant breast cancer
1999 · N. Kröger, W. Achterrath, et al. · Cancer Treatment Reviews · 65
Current status of radiant whole-body hyperthermia at temperatures >41.5°C and practical guidelines for the treatment of adults. The German ‘Interdisciplinary Working Group on Hyperthermia’
2004 · B. Hildebrandt, S. Hegewisch-Becker, et al. · International Journal of Hyperthermia · 54
PDF
Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604)
2008 · A. C. Reinacher-Schick, S. Kubicka, et al. · Journal of Clinical Oncology · 51
A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma
2003 · H Einsele, M Bamberg, et al. · Bone Marrow Transplantation · 45
Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group
2007 · F. Lordick, S. Lorenzen, et al. · Journal of Clinical Oncology · 39
Hyperuricemia and renal insufficiency associated with malignant disease: Urate oxidase as an efficient therapy?
1999 · Gunter Wolf, Susanne Hegewisch-Becker, et al. · American Journal of Kidney Diseases · 37
Colony-Stimulating Factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCFG) Recruit Myeloblastic and Lymphoblastic Leukemic Cells and Enhance the Cytotoxic Effects of Cytosine-Arabinoside
1990 · M. Andreeff, A. Tafuri, et al. · Hämatologie und Bluttransfusion · 35
Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
1998 · N Kröger, W Krüger, et al. · Bone Marrow Transplantation · 34
Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC)
2004 · S. Hegewisch-Becker, M. Sterneck, et al. · Journal of Clinical Oncology · 33
Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study – AIO SUP-0108
2016 · K. Jordan, T. Luetkens, et al. · European Journal of Cancer · 30
PDF
The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives
1996 · S. Hegewisch-Becker, D. K. Hossfeld · Annals of Hematology · 29
Ifosfamide, carboplatin and etoposide combined with 41.8°C whole body hyperthermia for malignant pleural mesothelioma
2003 · A Bakhshandeh, I Bruns, et al. · Lung Cancer · 25
Exacerbation of antiphospholipid antibody syndrome after treatment of localized cancer: a report of two cases
2002 · Langer F., Eifrig B., et al. · Annals of Hematology · 23
MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype.
1996 · S Hegewisch-Becker · PubMed · 23
Infusion of tumor-contaminated bone marrow for autologous rescue after high-dose therapy leading to long-term remission in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
1995 · S O Peters, M Stockschläder, et al. · PubMed · 22
Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group
2007 · W. H. Schmiegel, A. Reinacher-Schick, et al. · Journal of Clinical Oncology · 21
Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group
2013 · C. Giessen, U. Graeven, et al. · Annals of Oncology · 13
PDF
Works count: 76
Citation count: 1,846
H-index: 22
I10-index: 27
Year
Topic
Type